Navigation Links
OXiGENE Abstracts Published in ASCO Program

eve synergistic antitumor activity when administered concurrently. In animal studies, ZYBRESTAT has been shown to enhance the anti-tumor effects of several chemotherapeutic agents, several anti-angiogenic drugs, and radiation.

OXi4503 is a novel, second-generation vascular disrupting agent with potential intrinsic cytotoxicity exerted through an ortho-quinone metabolite. The drug candidate has demonstrated single-agent activity in human tumor xenograft models. Preclinical research with OXi4503 suggests that it not only shuts down tumor blood flow, but can also be metabolized into a compound which could assist with killing the remaining tumor cells at the periphery of the tumor by direct cytotoxic activity against tumor cells. In December 2004, the United Kingdom regulatory authorities accepted an application from our collaborators, Cancer Research UK, to initiate a dose-escalating Phase I clinical trial of OXi4503 in patients with advanced cancer. This trial is currently ongoing. In 2007, OXiGENE plans to initiate several preclinical studies to evaluate OXi4503 and possibly a Phase Ib clinical trial of OXi4503 in combination with an approved anti-angiogenic therapeutic.

About OXiGENE, Inc.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release including the initiation of further clinical trials with
'"/>




Page: 1 2 3 4

Related medicine technology :

1. OXiGENE Announces a Poster Presentation Highlighting Results from its Study of ZYBRETSTAT CA4P in Myopic Macular Degeneration (Study MMD-213) at the 47th Annual Meeting of the Association of Research in Vision and Ophthalmology
2. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
3. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
4. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
5. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
6. SciClone Announces ZADAXIN and SCV-07 Abstracts Accepted at ASCO
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
9. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
10. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
11. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OXiGENE Abstracts Published ASCO Program
(Date:11/23/2014)... Nov. 23, 2014 Anthera Pharmaceuticals, Inc. (Nasdaq: ... F. Truex , President and Chief Executive Officer, will ... Jaffray Healthcare Conference. Anthera will present ... Palace Hotel in New York City ... Anthera Pharmaceuticals is a biopharmaceutical company focused on developing ...
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
(Date:11/22/2014)... Nov. 21, 2014 Research and Markets  has ... Drug Industry Report, 2014-2017" report to their offering. ... The Chinese recombinant protein drug market has been expanding ... ability and the like. During 2005-2013, sales of recombinant ... a CAGR of 19.1%, and it is projected that ...
Breaking Medicine Technology:Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3
... , PRINCETON, N.J., Nov. 30 Covance ... present at the Piper Jaffray 21st Annual Health Care Conference on ... access a live webcast of the presentation at www.covance.com . ... log on 10 minutes early. , Covance, with headquarters in Princeton, ...
... , ... that a new market research report is available in ... Market Review , http://www.reportlinker.com/p0164331/Operating-Tables---A-World-Market-Review.html , Operating ... the best possible position for the surgeon to conduct ...
Cached Medicine Technology:Reportlinker Adds Operating Tables - A World Market Review 2Reportlinker Adds Operating Tables - A World Market Review 3Reportlinker Adds Operating Tables - A World Market Review 4Reportlinker Adds Operating Tables - A World Market Review 5
(Date:11/24/2014)... (PRWEB) November 24, 2014 SWAccessControl.com ... locks. As a matter of fact, the company is a ... its brand new magnetic locks are available at discounted prices, ... our new range of magnetic locks. This time, all of ... are popular at home and abroad, so I have confidence ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Gersowitz Libo & ... it has received national Tier recognition in the 2015 Edition ... a tiered ranking signals a unique combination of quality law ... proud to receive this honor and especially grateful to our ... important honor and ranking possible,” said Jeff S. Korek, senior ...
(Date:11/23/2014)... 24, 2014 For the coming special ... has launched a great promotion for many products, especially ... can get the best choice with amazing discounts, up ... Tidebuy.com. , It is easy to buy colored ... that, this selection is also famous for delicate craftsmanship, ...
(Date:11/23/2014)... (HealthDay News) -- Close friends have more influence on ... a new study says. "We,ve known for ... influence on individual alcohol use, but there are no ... and the friend group,s influence on those decisions," Jonathon ... Public Health, said in a university news release. ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers are ... announced its new collection of power suppliers. Additionally, it ... power suppliers. All the new models come with big ... until Dec. 20, 2014. , SWAccessControl.com has thousands of ... it for a long time. It is very wise ...
Breaking Medicine News(10 mins):Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2
... Xenical manufactured by GlaxoSmithkline got a nod for OTC ... Food// and Drug Administration so that it can be ... An estimated arrival time for the sale is early ... F.D.A.-approved weight-loss product sold without a doctor's prescription. The ...
... approximately 6,000 plus trampolining fractures were seen in 2002. ... guidelines// are needed to stem the rise in trampoline-related ... has found a "worrying trend" in the number of ... ,The Royal Berkshire in Reading was identified ...
... leukemia and dementia, was a regular with a day unit at ... decrepit clients. An ambulance team was in charge of picking her ... the residence. ,On August 20th 2003, the ambulance, instead ... of an empty house of another patient, after a key was ...
... of Edinburgh plan to study how nanoparticles affect the ... found// in pollution by traffic exhaust as well as ... even food can damage to the cells of the ... 80,000 times smaller than the thickness of a human ...
... According to the Research conducted by the scientists at ... present in the air may have an adverse// effect ... found in the pollution from traffic exhaust, household goods ... ,Nanoparticles are atoms and molecules 80,000 times smaller ...
... of measles in Fiji but so far there have not ... hands in an effort// to assist the Ministry of Health. ... worth of measles vaccines. The World Health Organization’s representative in ... 70 confirmed cases of measles in Fiji. ...
Cached Medicine News:Health News:Be cautious while on the Trampoline 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: